source
- TRex Bio prices $117M IPO to fund Treg-targeted immune therapiesTRex Bio announced pricing of its initial public offering at $117 million, selling 8,333,334 shares at $14 each, meeting the low end of its earlier guidance. The company will begin trading on Nasd…
- Study finds rising patent thickets may slow generic drug competitionA recent special communication in JAMA reports that the number of patents linked to FDA‑approved small‑molecule drugs has risen over the past 15 years. The increase is driven largely by non‑primary…